Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos M Galmarini

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Haematologica|July 5, 2006
Correlation of hENT1 expression and function with gemcitabine cytotoxicity in mantle cell lymphoma lines and clinical samplesCarlos M Galmarini
Current Opinion in Investigational Drugs (London, England : 2000)|November 28, 2009
Sagopilone, a microtubule stabilizer for the potential treatment of cancerCarlos M Galmarini
Journal of Experimental Therapeutics & Oncology|November 6, 2002
P-glycoprotein expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six chemotherapeutic drugsCarlos M Galmarini
International Journal of Chronic Diseases|June 23, 2020
Lessons from Hippocrates: Time to Change the Cancer ParadigmCarlos M Galmarini
Current Opinion in Investigational Drugs (London, England : 2000)|January 11, 2007
Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancerCarlos M Galmarini
Current Opinion in Investigational Drugs (London, England : 2000)|July 10, 2004
OSI-461 (OSI)Carlos M Galmarini
Current Opinion in Investigational Drugs (London, England : 2000)|June 21, 2006
Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancerCarlos M Galmarini
EXCLI Journal|December 14, 2020
Why we do what we do. A brief analysis of cancer therapiesCarlos M Galmarini
Current Opinion in Investigational Drugs (London, England : 2000)|January 15, 2005
Histamine dihydrochloride (subcutaneous) MaximCarlos M Galmarini
Leukemia Research|April 17, 2007
What does over-expression of cN-II enzyme signify in haematological malignancies?Carlos M Galmarini
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Haematologica|July 5, 2006
Correlation of hENT1 expression and function with gemcitabine cytotoxicity in mantle cell lymphoma lines and clinical samplesCarlos M Galmarini
Current Opinion in Investigational Drugs (London, England : 2000)|November 28, 2009
Sagopilone, a microtubule stabilizer for the potential treatment of cancerCarlos M Galmarini
Journal of Experimental Therapeutics & Oncology|November 6, 2002
P-glycoprotein expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six chemotherapeutic drugsCarlos M Galmarini
International Journal of Chronic Diseases|June 23, 2020
Lessons from Hippocrates: Time to Change the Cancer ParadigmCarlos M Galmarini
Current Opinion in Investigational Drugs (London, England : 2000)|January 11, 2007
Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancerCarlos M Galmarini
Current Opinion in Investigational Drugs (London, England : 2000)|July 10, 2004
OSI-461 (OSI)Carlos M Galmarini
Current Opinion in Investigational Drugs (London, England : 2000)|June 21, 2006
Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancerCarlos M Galmarini
EXCLI Journal|December 14, 2020
Why we do what we do. A brief analysis of cancer therapiesCarlos M Galmarini
Current Opinion in Investigational Drugs (London, England : 2000)|January 15, 2005
Histamine dihydrochloride (subcutaneous) MaximCarlos M Galmarini
Leukemia Research|April 17, 2007
What does over-expression of cN-II enzyme signify in haematological malignancies?Carlos M Galmarini
Pageof 8